Sarcoma Clinical Trial
Official title:
A Phase I Pilot Study of Tumor Cell - B Lymphoblastoid Cell Line Vaccination in Pediatric Subjects With Relapsed Ewing's Sarcoma and Neuroblastoma
RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body
build an effective immune response to kill tumor cells. Interleukin-2 (IL-2) may stimulate
the white blood cells to kill tumor cells. Biological therapies, such as cellular adoptive
immunotherapy, stimulate the immune system and stop tumor cells from growing. Giving vaccine
therapy with IL-2 may be a more effective treatment for Ewing's sarcoma or neuroblastoma.
PURPOSE: This phase I trial is studying the side effects of vaccine therapy when given with
IL-2 in treating young patients with relapsed or refractory Ewing's sarcoma or
neuroblastoma.
OBJECTIVES:
- Determine the safety of vaccination comprising autologous tumor cells fused with
Epstein-Barr virus-transformed B-lymphoblastoid cells followed by interleukin-2 (IL-2)
in children with relapsed or refractory Ewing's sarcoma or neuroblastoma.
- Determine antitumor immunity by examining cell phenotype and function in patients
treated with this vaccine and cytotoxic T lymphocytes (CTL).
- Determine the safety of CTL and IL-2 in these patients.
OUTLINE: This is a pilot study.
Tumor cells and blood cells are collected from patients and expanded in vitro. Tumor cells
and Epstein-Barr virus-transformed B-lymphoblastoid cells (derived from blood cells) are
fused together to produce the vaccine.
- Vaccination: Patients receive vaccine comprising autologous tumor cells fused with
Epstein-Barr virus-transformed B-lymphoblastoid cells subcutaneously (SC) once on days
0, 14, and 28 and interleukin-2 (IL-2) SC twice daily on days 1-7, 15-21, and 29-35.
- Cytotoxic T lymphocytes (CTL): After vaccination, patients with evidence of antitumor
immunity undergo leukapheresis to collect white blood cells for CTL expansion. Some of
these patients then receive CTL IV once on days 0, 14, and 28 and IL-2 SC twice daily
on days 1-7, 15-21, and 29-35.
Patients are followed weekly for 2 weeks, every 2 weeks for 1 month, monthly for 3 months,
and then every 2 months for up to 1 year post-vaccination. Patients who receive CTL are also
followed annually for survival.
PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study within 3 years.
;
Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04457258 -
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
|
Early Phase 1 | |
| Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
| Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
| Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Recruiting |
NCT04535713 -
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
|
Phase 2 | |
| Completed |
NCT03521531 -
Burden and Medical Care of Sarcoma in Germany
|
||
| Completed |
NCT02496520 -
Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults
|
Phase 1/Phase 2 | |
| Terminated |
NCT02054104 -
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
|
Phase 1/Phase 2 | |
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04577014 -
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT04052334 -
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
|
Phase 1 | |
| Completed |
NCT01593748 -
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
|
Phase 2 | |
| Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
| Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
| Completed |
NCT01879085 -
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04553692 -
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
|
Phase 1 | |
| Completed |
NCT01209598 -
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
|
Phase 2 | |
| Completed |
NCT04553471 -
Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers
|
N/A | |
| Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 |